Share

Congratulations to Dr. Hans Wildiers, winner of the B.J. Kennedy Geriatric Oncology Award

Congratulations to our longstanding member Dr. Hans Wildiers for receiving the B.J. Kennedy Geriatric Oncology Award at the 2023 ASCO Annual Meeting.

Created in 2007 in honour of B.J. Kennedy, MD, this award recognises an ASCO member who has made outstanding contributions to the research, diagnosis, and treatment of cancer in the elderly, and in bringing an understanding of geriatric oncology to fellows and junior faculty.

During the Award Lecture (session available on-demand for participants), Dr. Wildiers presented a session titled “Looking Back and Moving Forward” where he focused on the achievements in the field of geriatric oncology and the work that is still needed to improve the care of older patients with cancer.

During his presentation, he thanked organisations like EORTC, which have strongly supported geriatric oncology research in the last years.

“It is my great honour to receive this year’s the B.J. Kennedy Geriatric Oncology Award. […] Within the EORTC, we had a lot of discussions on the optimal trial design for older patients with cancer.”

– Dr. Hans Wildiers

Dr. Wildiers is a medical oncologist dedicated to breast cancer research. He has served as a staff member in the Department of Medical Oncology at the University Hospital Leuven, Belgium, since 2004. Since 2015, he has been the coordinator of the Leuven Multidisciplinary Breast Center. He has also been the coordinator of several academic studies in the field of breast cancer and geriatric oncology and is the author of more than 350 peer-reviewed papers. He has been active on the Board of the International Society of Geriatric Oncology for many years and served as the organisation’s president from 2018 to 2020. From 2009 to 2015, he chaired the Cancer in the Elderly Task Force of the European Organisation for Research and Treatment of Cancer (EORTC).

More information here.

Back to news list

Related News

  • EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma

  • Minister F. Vandenbroucke visits EORTC Headquarters to strengthen collaborative efforts in clinical cancer research

  • IMMUcan has completed patient enrolment

  • EORTC SPRINT clinical cancer study receives support from Rising Tide Foundation to reduce the burden for patients

  • Pink October at EORTC: Over 60 years of impactful breast cancer research

  • Spotlight on ENA 2024 News

  • Do regulations and policies undermine the social value of independent academic research?

  • EORTC Quality of Life Group’s participation to ISOQOL 2024

  • New Insights into Glioblastoma Treatment for Older Adults Patients

  • TOPGEAR trial results show no significant benefit of preoperative chemoradiotherapy on long term survival